Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients

Phase

N/A

Condition

Pancreatic Cancer

Digestive System Neoplasms

Pancreatitis

Treatment

Irinotecan liposome II combination therapy regimen

Clinical Study ID

NCT06375473

MA-PC-RWS-011

Ages 18-100
All Genders

Study Summary

This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients with pancreatic ductal adenocarcinoma diagnosed by pathology or imaging;
Age ≥18 years old, male or female;
Patients receiving treatment based on irinotecan hydrochloride liposome injection II;
The subjects voluntarily joined the study and signed the informed consent.

Exclusion

Exclusion Criteria:

Confirmed pregnant or lactating women;
The researchers determined that other conditions were not suitable for inclusion inthe study.

Study Design

Irinotecan liposome II combination therapy regimen

April 19, 2024

April 19, 2027

Connect with a study center

Peking Union Medical College Hospital
Beijing, Beijing 100730
China
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.